TN2018000069A1 - Methods and compositions for treating conditions associated with an abnormal inflammatory responses - Google Patents
Methods and compositions for treating conditions associated with an abnormal inflammatory responsesInfo
- Publication number
- TN2018000069A1 TN2018000069A1 TNP/2018/000069A TN2018000069A TN2018000069A1 TN 2018000069 A1 TN2018000069 A1 TN 2018000069A1 TN 2018000069 A TN2018000069 A TN 2018000069A TN 2018000069 A1 TN2018000069 A1 TN 2018000069A1
- Authority
- TN
- Tunisia
- Prior art keywords
- methods
- cocrystal
- hydrate
- compositions
- compound
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000020053 Abnormal inflammatory response Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 229960001920 niclosamide Drugs 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 239000004061 uncoupling agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562213016P | 2015-09-01 | 2015-09-01 | |
| US201562241508P | 2015-10-14 | 2015-10-14 | |
| PCT/US2016/050012 WO2017040864A1 (en) | 2015-09-01 | 2016-09-01 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2018000069A1 true TN2018000069A1 (en) | 2019-07-08 |
Family
ID=58097295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP/2018/000069A TN2018000069A1 (en) | 2015-09-01 | 2016-09-01 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses |
Country Status (21)
| Country | Link |
|---|---|
| US (11) | US10292951B2 (https=) |
| EP (1) | EP3344274A4 (https=) |
| JP (2) | JP6955648B2 (https=) |
| KR (1) | KR20180080189A (https=) |
| CN (1) | CN109562137A (https=) |
| AU (2) | AU2016315852B2 (https=) |
| BR (1) | BR112018004069A2 (https=) |
| CA (1) | CA2997136A1 (https=) |
| CL (1) | CL2021000622A1 (https=) |
| CO (1) | CO2018003465A2 (https=) |
| CR (1) | CR20180185A (https=) |
| EA (1) | EA201890618A1 (https=) |
| HK (1) | HK1258048A1 (https=) |
| IL (1) | IL257801A (https=) |
| MX (3) | MX2018002586A (https=) |
| PE (1) | PE20181295A1 (https=) |
| PH (1) | PH12018500448A1 (https=) |
| SG (1) | SG10201914118SA (https=) |
| TN (1) | TN2018000069A1 (https=) |
| UA (1) | UA125747C2 (https=) |
| WO (1) | WO2017040864A1 (https=) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PL2315756T3 (pl) | 2008-07-08 | 2015-02-27 | Incyte Holdings Corp | 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy |
| PT3061821T (pt) | 2009-07-22 | 2019-09-05 | PureTech Health LLC | Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| EP3967312A1 (en) | 2014-09-12 | 2022-03-16 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| CN104880428B (zh) * | 2015-06-23 | 2016-07-06 | 山西振东安特生物制药有限公司 | 一种胶体果胶铋或含胶体果胶铋制剂中铋含量的测定方法 |
| EA201890618A1 (ru) | 2015-09-01 | 2018-10-31 | Ферст Вэйв Байо, Инк. | Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами |
| EP3370699A1 (en) * | 2015-11-04 | 2018-09-12 | Incyte Corporation | Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor |
| GB201604484D0 (en) | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
| US11278551B2 (en) | 2017-03-15 | 2022-03-22 | Georgetown University | Treating cancer with a CCK receptor inhibitor and an immune checkpoint inhibitor |
| US11147779B2 (en) * | 2017-03-21 | 2021-10-19 | Supreet K. Deshpande | Therapeutic agent for phosphodiesterase inhibition and its related disorders |
| AU2018263868A1 (en) | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| KR102459936B1 (ko) * | 2017-10-13 | 2022-10-27 | 주식회사 엘지생활건강 | 알칸닌을 포함하는 구강질환 예방 또는 치료용 조성물 |
| US10933061B2 (en) | 2017-12-21 | 2021-03-02 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate therapies and methods of use |
| EP3773579A4 (en) | 2018-03-26 | 2022-03-09 | Clear Creek Bio, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE |
| PL3817751T3 (pl) | 2018-07-03 | 2025-09-08 | Fennec Pharmaceuticals, Inc. | Postacie użytkowe bezwodnego tiosiarczanu sodu |
| IL261670B (en) * | 2018-09-06 | 2019-06-30 | Tudu Holdings Ltd | Magnesium-containing formulation and uses thereof |
| CN109180600A (zh) * | 2018-09-21 | 2019-01-11 | 五邑大学 | 一种麝香草酚类似物及其应用 |
| KR102408292B1 (ko) * | 2018-09-28 | 2022-06-10 | 카루나 세러퓨틱스 인코포레이티드 | 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3639822A1 (en) * | 2018-10-15 | 2020-04-22 | Universität Regensburg | Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion |
| KR102885113B1 (ko) | 2018-10-18 | 2025-11-13 | 머크 샤프 앤드 돔 엘엘씨 | 항-rsv 항체의 제제 및 그의 사용 방법 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN120842406A (zh) | 2018-10-31 | 2025-10-28 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| CN113316458B (zh) | 2018-11-07 | 2024-08-02 | 默沙东有限责任公司 | 抗lag3抗体和抗pd-1抗体的共制剂 |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
| CA3133804A1 (en) * | 2019-03-22 | 2020-10-01 | Mannkind Corporation | Inhalable dry powders |
| JP7730548B2 (ja) * | 2019-04-18 | 2025-08-28 | プリヴェップ インコーポレイテッド | 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法 |
| CN111032030B (zh) * | 2019-04-28 | 2023-02-17 | 深圳市中医院 | 氯硝柳胺乙醇胺盐在制备治疗系统性红斑狼疮及其并发症的药物中的应用 |
| CN112007036B (zh) * | 2019-05-29 | 2022-01-21 | 百岳特生物科技（上海）有限公司 | 化合物及其组合物用于制备缓解肺上皮细胞发炎的医药品的用途 |
| CN110200935B (zh) * | 2019-06-03 | 2021-03-02 | 浙江得恩德制药股份有限公司 | 一种胶体果胶铋胶囊及其制备工艺 |
| CN117660024A (zh) * | 2019-07-08 | 2024-03-08 | 株式会社Moresco | 微型乳剂、用于制造微型乳剂的方法以及微型乳剂的用途 |
| CN112341397B (zh) * | 2019-08-09 | 2023-05-23 | 成都苑东生物制药股份有限公司 | 吡嗪类衍生物或盐、异构体、其制备方法及用途 |
| EP3797771B1 (en) * | 2019-09-03 | 2022-02-23 | Square Power Ltd | Rebamipide for use in prophylaxis and treatment of celiac disease |
| US20210114973A1 (en) * | 2019-10-18 | 2021-04-22 | First Wave Bio, Inc. | Pharmaceutical formulations |
| KR102300846B1 (ko) * | 2019-11-01 | 2021-09-09 | 서울대학교산학협력단 | 면역 활성 개선용 조성물 및 이의 방법 |
| CN111122523B (zh) * | 2019-12-06 | 2021-09-28 | 山西大学 | 一种快速识别Ag+和Cys的三相输出功能的分子逻辑门及其构建方法 |
| US20230102999A1 (en) | 2020-01-10 | 2023-03-30 | First Wave Bio, Inc. | Deuterated niclosamide |
| WO2021142240A1 (en) | 2020-01-10 | 2021-07-15 | First Wave Bio, Inc. | Compositions comprising niclosamide for use in treating conditions associated with an abnormal inflammatory response |
| US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| TW202200121A (zh) | 2020-03-16 | 2022-01-01 | 美商費斯特威弗生技股份有限公司 | 治療方法 |
| AU2021237818A1 (en) * | 2020-03-19 | 2022-09-29 | Ferring Ventures Ltd. | Temperature-responsive virus storage system |
| US20210300873A1 (en) | 2020-03-20 | 2021-09-30 | Clear Creek Bio, Inc. | Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof |
| CN112914547A (zh) * | 2020-03-22 | 2021-06-08 | 复旦大学附属华山医院 | 内源性神经干细胞磁共振无创性示踪技术体系及建立方法 |
| US11045434B1 (en) * | 2020-04-01 | 2021-06-29 | UNION therapeutics A/S | Niclosamide formulations for treating disease |
| CA3172166A1 (en) * | 2020-04-01 | 2021-10-07 | Morten Sommer | Formulation |
| US20210346324A1 (en) * | 2020-05-05 | 2021-11-11 | NeuroBo Therapeutics, Inc. | Niclosamide Formulations and Methods of Use |
| US20230172885A1 (en) * | 2020-05-13 | 2023-06-08 | The Regents Of The University Of California | Thiol-containing compounds for use in treating coronavirus |
| WO2021231397A1 (en) | 2020-05-13 | 2021-11-18 | The Regents Of The University Of California | Thiosaccharides for use in treating coronavirus infection |
| CN112057623A (zh) * | 2020-06-03 | 2020-12-11 | 江苏靶标生物医药研究所有限公司 | 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用 |
| US12569481B2 (en) | 2020-06-12 | 2026-03-10 | Vanderbilt University | Methods of treatment for gastrointestinal motility disorders |
| WO2021255218A1 (en) * | 2020-06-19 | 2021-12-23 | Charité - Universitätsmedizin Berlin | A pharmaceutical combination comprising an anti-viral protonophore and a serine protease inhibitor |
| CN111650307A (zh) * | 2020-07-13 | 2020-09-11 | 重庆医药高等专科学校 | 一种同时对酒中解热镇痛类药品非法添加物定性定量检测的方法及应用 |
| CN116322669A (zh) * | 2020-07-23 | 2023-06-23 | 普渡研究基金会 | 治疗sars-cov-2、其它病毒性疾病和癌症的ohpp配制的氯硝柳胺 |
| AU2021325965A1 (en) * | 2020-08-14 | 2023-03-16 | Mayo Foundation For Medical Education And Research | Methods and materials for tissue ablation |
| WO2022046668A1 (en) * | 2020-08-22 | 2022-03-03 | Luc Montagnier | Compositions and methods for reducing the transmissivity of illnesses |
| CN111920824A (zh) * | 2020-09-11 | 2020-11-13 | 余朝权 | 一种治疗伤口的中药组合物 |
| KR102636847B1 (ko) | 2020-09-18 | 2024-02-19 | 경북대학교 산학협력단 | 티아민 유도체를 포함하는 이식편대숙주질환 예방 또는 치료용 약학적 조성물 |
| CN114246852B (zh) * | 2020-09-21 | 2024-08-16 | 暨南大学 | 一种药物组合物在心脑血管疾病中的应用 |
| KR102378590B1 (ko) * | 2020-09-28 | 2022-03-24 | (주)위바이오트리 | 난용성 약물을 포함하는 금속 (수)산화물 복합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| WO2022093871A1 (en) * | 2020-10-26 | 2022-05-05 | The Regents Of The University Of California | Sars-c0v-2 inactivation by ethacridine |
| CN112342028B (zh) * | 2020-10-28 | 2021-07-09 | 中铁建华南建设(广州)高科技产业有限公司 | 盾构分散剂及其制备方法和应用 |
| WO2022091065A1 (ko) * | 2020-11-02 | 2022-05-05 | (주)아이엠디팜 | 신규한 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법 |
| CN112526032B (zh) * | 2020-12-28 | 2022-05-17 | 北京金城泰尔制药有限公司 | 聚甲酚磺醛的检测方法 |
| WO2022147499A1 (en) * | 2021-01-04 | 2022-07-07 | Neurobo Pharmaceuticals, Inc. | Method of treating viral infections with a combination of niclosamide and gemcabene |
| JP7504304B2 (ja) | 2021-01-19 | 2024-06-21 | エリモス・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー | コロナウイルス抗ウイルス剤としてのテラメプロコールおよびノルジヒドログアイアレチン酸（ｎｄｇａ）誘導体 |
| WO2022162604A1 (ko) * | 2021-01-28 | 2022-08-04 | (주)아이엠디팜 | 카모스타트 및 니클로사마이드를 포함하는 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법 |
| CN112826795B (zh) * | 2021-03-23 | 2022-08-30 | 重庆医科大学 | 一种载汉防己甲素脂质体制剂及其制备方法和应用 |
| WO2022204397A1 (en) * | 2021-03-26 | 2022-09-29 | First Wave Biopharma | Treatment of long haulers syndrome with niclosamide |
| CN113368064B (zh) * | 2021-06-08 | 2022-06-28 | 吉林津升制药有限公司 | 一种烟酸冻干粉及其制备方法 |
| CN114134195B (zh) * | 2021-11-03 | 2024-06-11 | 南方科技大学 | 预防前列腺癌的药剂的筛选方法、硝唑尼特在制药中的应用 |
| WO2023096896A2 (en) * | 2021-11-23 | 2023-06-01 | nference, inc. | Detection of covid-19 associated cardiac injury and vaccine-associated myocarditis |
| CN113908154A (zh) * | 2021-11-29 | 2022-01-11 | 中国药科大学 | 硝唑尼特及其体内代谢物替唑尼特在抗银屑病及银屑病样皮肤炎症中的应用 |
| CN114393662A (zh) * | 2021-12-21 | 2022-04-26 | 凭祥青山中密度纤维板有限公司 | 一种环保中密度纤维板的制备方法 |
| WO2023147169A2 (en) * | 2022-01-31 | 2023-08-03 | LIVIONEX, Inc. | Novel liquid formulations for iron chelation |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| CN114796135B (zh) * | 2022-03-29 | 2023-04-07 | 海南久常制药有限公司 | 一种硫糖铝口服制剂及其制备方法 |
| CN114652734A (zh) * | 2022-03-31 | 2022-06-24 | 李红梦 | 一种祛痘的药物组合物及其制备方法 |
| CN114767871B (zh) * | 2022-04-19 | 2023-04-07 | 中国工程物理研究院机械制造工艺研究所 | 介孔硅载药体系及制备方法和介孔硅载药 |
| CN117045657A (zh) * | 2022-05-12 | 2023-11-14 | 广州嘉越医药科技有限公司 | 一种药物组合及其应用 |
| WO2024029639A1 (ko) * | 2022-08-02 | 2024-02-08 | 제이투에이치바이오텍 주식회사 | 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도 |
| CN115494231A (zh) * | 2022-09-02 | 2022-12-20 | 武汉三鹰生物技术有限公司 | 一种蛋白酶抑制剂混合物及其制备方法与应用 |
| CN115739028B (zh) * | 2022-11-26 | 2024-04-02 | 西南政法大学 | 一种精神活性物质吸附剂及其应用 |
| CN116036289B (zh) * | 2023-02-03 | 2025-05-06 | 中国药科大学 | 一种增强铁死亡治疗效果的纳米制剂及其制备方法和应用 |
| CN116077424B (zh) * | 2023-02-17 | 2025-06-03 | 重庆大学 | 一种多功能仿生水凝胶及其制备方法和应用 |
| WO2024182078A1 (en) * | 2023-02-28 | 2024-09-06 | Verté Therapeutics, Llc | Veterinary transdermal gel comprising ondansetron, and related methods |
| CN116139116A (zh) * | 2023-03-30 | 2023-05-23 | 中南大学湘雅医院 | 氯硝柳胺在抑制急性肝衰竭中的应用 |
| CN116531366B (zh) * | 2023-05-23 | 2025-02-14 | 新乡医学院 | 罗替戈汀的药物新用途 |
| WO2025037323A1 (en) * | 2023-08-12 | 2025-02-20 | Pavan Kumar Kothapuvari | Pharmaceutical compositions for treatment of dry eye disease and associated disorders |
| KR102921518B1 (ko) * | 2023-09-04 | 2026-02-03 | 숭실대학교 산학협력단 | 니클로사마이드 및 피콜린산으로 이루어진 공결정, 이의 제조방법 및 이의 의학적 용도 |
| CN117180223A (zh) * | 2023-09-25 | 2023-12-08 | 浙江大学医学院附属第一医院 | 一种负载硝呋齐特的巨噬细胞递药系统及其应用 |
| CN117357509B (zh) * | 2023-09-28 | 2026-04-03 | 华中科技大学 | 一种吲哚菁绿稳定的CuET纳米颗粒、纳米颗粒分散液及其制备方法和应用 |
| CN117883443A (zh) * | 2023-12-12 | 2024-04-16 | 中国海洋大学 | 吡罗克酮乙醇胺盐在制备治疗胃肠道疾病的药物中的应用 |
| CN117899225A (zh) * | 2024-01-19 | 2024-04-19 | 芮城绿曼生物药业有限公司 | 一种增强免疫力的兽用抗菌注射剂、制备方法及应用 |
| WO2025216846A1 (en) * | 2024-04-12 | 2025-10-16 | Advancion Corporation | Metalworking fluid compositions including 3-amino-2-butanol and uses thereof |
| CN119055625B (zh) * | 2024-07-23 | 2025-09-09 | 湖北工业大学 | Tiratricol在制备抗ADV7病毒药物中的应用 |
| CN120204184A (zh) * | 2025-02-17 | 2025-06-27 | 深圳市第三人民医院(深圳市肝病研究所) | 阿米替林和/或其衍生物的应用、结核分枝杆菌抑制剂和药物组合物 |
| CN119700664B (zh) * | 2025-02-28 | 2025-06-20 | 山东新时代药业有限公司 | 含有活性成分琥珀酸普芦卡必利的注射液及其制备方法 |
| CN120713881B (zh) * | 2025-08-21 | 2025-12-05 | 南方科技大学 | 氯硝柳胺在治疗器官移植排斥反应中的应用 |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3079297A (en) | 1960-05-31 | 1963-02-26 | Bayer Ag | Method of combating gastropods |
| US3927195A (en) * | 1974-01-31 | 1975-12-16 | Lilly Industries Ltd | Production of capsules |
| FR2505798B1 (fr) | 1981-05-14 | 1986-07-25 | Pari Symac | Perfectionnement aux dispositifs comportant un ressort helicoidal utilise comme organe de transfert, d'extraction, de dosage ou de melange |
| NZ223200A (en) | 1988-01-15 | 1989-01-06 | Ancare Distributors | Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier |
| DE4005528C2 (de) | 1990-02-22 | 1998-01-15 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
| US5280784A (en) | 1990-09-19 | 1994-01-25 | Paul Ritzau Pari-Werk Gmbh | Device in particular and inhalating device for treating the lung and the respiratory tracts |
| DE59107894D1 (de) | 1991-03-21 | 1996-07-11 | Ritzau Pari Werk Gmbh Paul | Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie |
| DK0540774T3 (da) | 1991-11-07 | 1995-07-10 | Ritzau Pari Werk Gmbh Paul | Væskeforstøver |
| DK0540775T3 (da) | 1991-11-07 | 1997-08-25 | Ritzau Pari Werk Gmbh Paul | Forstøver især til anvendelse i apparater til inhalationsterapi |
| DE4225928A1 (de) | 1992-08-05 | 1994-02-10 | Ritzau Pari Werk Gmbh Paul | Zerstäubervorrichtung mit Heizeinrichtung |
| US5914132A (en) | 1993-02-26 | 1999-06-22 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| DE4310575C1 (de) | 1993-03-31 | 1994-09-15 | Ritzau Pari Werk Gmbh Paul | Vorrichtung zum Erzeugen von Aerosolpulsen |
| EP0663241B1 (de) | 1993-12-17 | 1998-07-15 | PARI GmbH Spezialisten für effektive Inhalation | Zerstäuberdüse |
| GB9412394D0 (en) | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
| US6000394A (en) | 1994-10-26 | 1999-12-14 | Paul Rizau Pari-Werk Gmbh | Generation of an aerosol of an exact dose |
| US5663155A (en) * | 1994-11-30 | 1997-09-02 | The University Hospital | Compositions for the treatment of parasitic infections |
| DE19520622C2 (de) | 1995-06-06 | 2003-05-15 | Pari Gmbh | Vorrichtung zum Vernebeln von Fluiden |
| DE19602628C2 (de) | 1996-01-25 | 2000-06-29 | Pari Gmbh | Vernebler |
| EP0821970A1 (en) | 1996-08-02 | 1998-02-04 | Edward Henri Charles Verhaeren | Carrier composition for influencing the tight junction permeability |
| US6503881B2 (en) | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| DE19734022C2 (de) | 1997-08-06 | 2000-06-21 | Pari Gmbh | Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses |
| US5905090A (en) | 1998-04-29 | 1999-05-18 | Italfarmaco S.P.A. | Analogues of the active metabolite of leflunomide |
| UA69413C2 (uk) | 1998-05-22 | 2004-09-15 | Брістол-Майерс Сквібб Компані | Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції |
| DE19827228C2 (de) | 1998-06-18 | 2000-07-13 | Pari Gmbh | Flüssigkeitszerstäubervorrichtung |
| EP1098641B1 (en) | 1998-07-27 | 2016-04-27 | St. Jude Pharmaceuticals, Inc. | Chemically induced intracellular hyperthermia |
| US6653309B1 (en) | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
| DE19962110C2 (de) | 1999-12-22 | 2003-06-12 | Pari Gmbh | Inhalationsvernebler mit einstückigem Ventilelement |
| AU2001260083A1 (en) * | 2000-05-26 | 2001-12-03 | Dr. Reddy's Research Foundation | New pharmaceutical composition and the process for its preparation |
| KR20090090406A (ko) | 2000-12-18 | 2009-08-25 | 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 | 염증성 사이토카인 생산 유리 억제제 |
| KR20030064852A (ko) | 2000-12-22 | 2003-08-02 | 이시하라 산교 가부시끼가이샤 | 아닐린 유도체 또는 그의 염 및 이들을 함유하는사이토카인 생산 억제제 |
| CA2436418A1 (en) | 2001-01-30 | 2002-08-08 | Board Of Regents, The University Of Texas Systems | Process for production of nanoparticles and microparticles by spray freezing into liquid |
| US20040022861A1 (en) | 2001-01-30 | 2004-02-05 | Williams Robert O. | Process for production of nanoparticles and microparticles by spray freezing into liquid |
| US20040071757A1 (en) | 2001-11-20 | 2004-04-15 | David Rolf | Inhalation antiviral patch |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| AU2003249244A1 (en) | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| EP1589948A1 (en) | 2003-01-15 | 2005-11-02 | Dow Global Technologies Inc. | Drug particles obtained by freezing onto a cold surface |
| US7544712B1 (en) | 2003-05-28 | 2009-06-09 | National Health Research Insitutes | Treatment of coronavirus infection |
| US20050123571A1 (en) | 2003-06-06 | 2005-06-09 | Rossini Aldo A. | Modulation of apoptosis |
| US7249224B2 (en) | 2003-08-05 | 2007-07-24 | Newisys, Inc. | Methods and apparatus for providing early responses from a remote data cache |
| DE10340277B4 (de) | 2003-08-29 | 2006-11-23 | Bio-Gate Bioinnovative Materials Gmbh | Körperpflegemittel mit Silber-Agglomeraten |
| WO2006014529A1 (en) | 2004-07-07 | 2006-02-09 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating obesity |
| CN1626506A (zh) | 2004-08-10 | 2005-06-15 | 李志良 | 高纯度、高收率氯硝柳胺的制备 |
| US9061027B2 (en) | 2004-08-27 | 2015-06-23 | Board Of Regents, The University Of Texas System | Enhanced delivery of drug compositions to treat life threatening infections |
| WO2006120178A1 (en) | 2005-05-11 | 2006-11-16 | Novo Nordisk A/S | New haloalkylsulfone substituted compounds useful for treating obesity and diabetes |
| JP2008545677A (ja) | 2005-05-23 | 2008-12-18 | ノボ ノルディスク アクティーゼルスカブ | 新規なハロアルコキシ置換サリチル酸アニリド |
| GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
| WO2008021088A2 (en) | 2006-08-08 | 2008-02-21 | The Regents Of The University Of Californina | Salicylanilides enhance oral delivery of therapeutic peptides |
| CA2678455C (en) | 2007-01-10 | 2019-02-12 | Board Of Regents The University Of Texas System | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery |
| EP2170283B1 (en) | 2007-06-22 | 2019-01-09 | Board of Regents, The University of Texas System | Formation of stable submicron peptide or protein particles by thin film freezing |
| US8262657B2 (en) | 2007-08-16 | 2012-09-11 | Nutek Orthopaedics, Inc. | External fixation apparatus with adjustable pin clamping means and convergent bone pins |
| WO2009086940A1 (en) | 2008-01-10 | 2009-07-16 | Evonik Röhm Gmbh | Coated pharmaceutical or nutraceutical preparation with enhanced active substance release in the colon |
| NO2252275T3 (https=) | 2008-02-13 | 2018-04-28 | ||
| EP2123626A1 (en) | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
| US20100215782A1 (en) | 2008-10-22 | 2010-08-26 | Metaproteomics, Llc | Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis |
| CU23701A1 (es) * | 2008-12-29 | 2011-09-21 | Ct Ingenieria Genetica Biotech | Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i |
| AP2012006064A0 (en) | 2009-06-26 | 2012-02-29 | Romark Lab Lc | Compounds and methods for treating influenza. |
| CN101601670B (zh) | 2009-06-30 | 2014-06-04 | 青岛蔚蓝生物股份有限公司 | 一种宠物用复方氯硝柳胺驱虫片剂及其制备方法 |
| KR100990110B1 (ko) | 2009-08-18 | 2010-10-29 | 엘지전자 주식회사 | 태양 전지 |
| US20130005802A1 (en) | 2009-09-21 | 2013-01-03 | Wei Chen | Treatment of wnt/frizzled-related diseases |
| US9206394B2 (en) | 2010-02-03 | 2015-12-08 | The University Of Tokyo | Method for reconstructing immune function using pluripotent stem cells |
| GB201015079D0 (en) | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US20130231312A1 (en) | 2010-11-16 | 2013-09-05 | Shengkan Jin | Treatment of type ii diabetes and diabetes-associated diseases with safe chemical mitochondrial uncouplers |
| ES2647072T3 (es) | 2011-04-18 | 2017-12-19 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Niclosamida para el tratamiento de la metástasis en el cáncer |
| US9572820B2 (en) | 2011-05-10 | 2017-02-21 | Stc.Unm | Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits |
| EP2731605A4 (en) * | 2011-07-15 | 2015-02-25 | Sla Pharma Ag | Pharmaceutical compositions for rectal administration |
| JP6238969B2 (ja) | 2012-05-08 | 2017-11-29 | エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． | 新規方法 |
| WO2014023329A1 (en) | 2012-08-06 | 2014-02-13 | Life And Brain Gmbh | Niclosamide and its derivatives for use in the treatment of solid tumors |
| CN102861014A (zh) * | 2012-10-16 | 2013-01-09 | 天津必佳药业集团有限公司 | 一种畜禽用抗蠕虫病复方氯硝柳胺片及其制备方法 |
| CN103891720B (zh) * | 2012-12-27 | 2016-02-17 | 陕西汤普森生物科技有限公司 | 一种含有螺枯威的复配杀螺组合物 |
| CN105142631A (zh) | 2013-01-14 | 2015-12-09 | 健康诊所有限公司 | 抗癌药物和用途 |
| US9138425B2 (en) * | 2013-03-12 | 2015-09-22 | Patheon Inc. | Drug delivery system to increase bioavailability |
| ES2706152T3 (es) | 2013-04-23 | 2019-03-27 | Zx Pharma Llc | Composición entérica de múltiples partículas revestida con subrevestimiento proteico |
| WO2014185973A2 (en) | 2013-05-14 | 2014-11-20 | The University Of Chicago | Modulation of reactivation of a latent virus |
| US20160136123A1 (en) * | 2013-06-14 | 2016-05-19 | Vojo P. Deretic | Treatment of autophagy-related disorders |
| CA2954168C (en) | 2013-08-02 | 2023-09-19 | The Regents Of The University Of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| WO2015065919A1 (en) * | 2013-10-28 | 2015-05-07 | The Regents Of The University Of California | Treatment of metastatic prostate cancer |
| NZ760541A (en) | 2014-01-10 | 2022-08-26 | Avalyn Pharma Inc | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| CN103751854B (zh) | 2014-01-20 | 2015-08-26 | 瞿介明 | 抗菌医用导管 |
| KR102207381B1 (ko) | 2014-10-23 | 2021-01-27 | 싱 몰레큘러 메디신, 엘엘씨 | 세포내 항원에 대해 지향된 단일 도메인 항체 |
| UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| JP6047203B2 (ja) | 2015-02-20 | 2016-12-21 | セルセウティックス コーポレイション | 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬 |
| US9566399B1 (en) | 2015-04-14 | 2017-02-14 | Clempharma LLC | Deep lung alveolar aerosol targeted drug delivery |
| JP6940416B2 (ja) | 2015-05-01 | 2021-09-29 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 多剤脆性マトリックス組成物 |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| CN105063018A (zh) * | 2015-08-31 | 2015-11-18 | 山西大学 | 一种从葡萄成熟果实中提取总rna的方法 |
| EA201890618A1 (ru) | 2015-09-01 | 2018-10-31 | Ферст Вэйв Байо, Инк. | Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами |
| EP3168211A1 (en) | 2015-11-10 | 2017-05-17 | Westfälische Wilhelms-Universität Münster | Pharmaceutical co-crystals of niclosamide |
| US10189797B2 (en) | 2015-12-30 | 2019-01-29 | Duke University | Chemical modulators of immune checkpoints and therapeutic use |
| US10588864B2 (en) | 2016-03-11 | 2020-03-17 | Gateway Pharmaceuticals LLC | Pharmaceutical compositions for colon-specific delivery |
| WO2017223491A1 (en) | 2016-06-23 | 2017-12-28 | Health Research, Inc. | Pharmaceutical compositions with antiflaviviral activity |
| US20180015153A1 (en) | 2016-07-16 | 2018-01-18 | Florida State University Research Foundation, Inc. | Compounds and methods for treatment and prevention of flavivirus infection |
| KR101928543B1 (ko) | 2017-01-09 | 2018-12-13 | 사단법인 분자설계연구소 | 니클로사마이드를 함유하는 Axin-GSK3 단백질 결합 관련 질환 치료용 약학조성물 |
| WO2018136559A1 (en) | 2017-01-17 | 2018-07-26 | The Regents Of The University Of California | Methods for treating flaviviruses and zika infections |
| EP3576755A4 (en) | 2017-02-02 | 2020-12-02 | McMaster University | BICARBONATE AS A POTENTIALIZER OF ANTIMICROBIAL AGENTS |
| US11147779B2 (en) | 2017-03-21 | 2021-10-19 | Supreet K. Deshpande | Therapeutic agent for phosphodiesterase inhibition and its related disorders |
| FI3612262T3 (fi) | 2017-04-18 | 2024-01-16 | Inspiring Pty Ltd | Kuivajauheinhalaattori ja kuivajauheinhalaattorin tilanjatkeväline |
| WO2018205016A1 (en) | 2017-05-08 | 2018-11-15 | The Governors Of The University Of Alberta | Peroxisome biomarkers in hiv disease progression and peroxisome activating drugs for hiv treatment |
| WO2018213834A1 (en) | 2017-05-19 | 2018-11-22 | Pneuma Respiratory, Inc. | Dry powder delivery device and methods of use |
| US20200206139A1 (en) | 2017-09-11 | 2020-07-02 | Board Of Regents, The University Of Texas System | Compositions for the improved delivery of drugs |
| US20200405643A1 (en) | 2017-09-11 | 2020-12-31 | Board Of Regents, The University Of Texas System | Drug compositions containing porous carriers made by thermal or fusion-based processes |
| EP3727418B1 (en) | 2017-12-21 | 2026-04-08 | Merz Pharmaceuticals, LLC | Surfactant formulations for inhalation |
| WO2019147626A1 (en) | 2018-01-23 | 2019-08-01 | The Trustees Of Columbia University In The City Of New York | Activation of mitochondrial uncoupling as a therapeutic intervention |
| WO2019217164A1 (en) | 2018-05-09 | 2019-11-14 | Reyoung Corporation | Compositions and methods for treating cancer and other diseases |
| US11166926B2 (en) | 2018-08-08 | 2021-11-09 | The Hospital For Sick Children | Compositions and methods for protecting a host from enteric toxigenic pathogens |
| BR112022003434A2 (pt) | 2019-08-23 | 2022-05-24 | Dae Woong Pharma | Composição de liberação retardada de niclosamida e uso antiviral da mesma |
| US20210114973A1 (en) | 2019-10-18 | 2021-04-22 | First Wave Bio, Inc. | Pharmaceutical formulations |
| US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| US11045434B1 (en) | 2020-04-01 | 2021-06-29 | UNION therapeutics A/S | Niclosamide formulations for treating disease |
-
2016
- 2016-09-01 EA EA201890618A patent/EA201890618A1/ru unknown
- 2016-09-01 CN CN201680063216.XA patent/CN109562137A/zh active Pending
- 2016-09-01 US US15/255,102 patent/US10292951B2/en active Active
- 2016-09-01 CR CR20180185A patent/CR20180185A/es unknown
- 2016-09-01 AU AU2016315852A patent/AU2016315852B2/en not_active Ceased
- 2016-09-01 MX MX2018002586A patent/MX2018002586A/es unknown
- 2016-09-01 TN TNP/2018/000069A patent/TN2018000069A1/en unknown
- 2016-09-01 UA UAA201802287A patent/UA125747C2/uk unknown
- 2016-09-01 JP JP2018530676A patent/JP6955648B2/ja not_active Expired - Fee Related
- 2016-09-01 WO PCT/US2016/050012 patent/WO2017040864A1/en not_active Ceased
- 2016-09-01 PE PE2018000333A patent/PE20181295A1/es unknown
- 2016-09-01 CA CA2997136A patent/CA2997136A1/en active Pending
- 2016-09-01 KR KR1020187009287A patent/KR20180080189A/ko not_active Ceased
- 2016-09-01 SG SG10201914118SA patent/SG10201914118SA/en unknown
- 2016-09-01 HK HK19100425.4A patent/HK1258048A1/zh unknown
- 2016-09-01 BR BR112018004069-0A patent/BR112018004069A2/pt not_active IP Right Cessation
- 2016-09-01 EP EP16843029.6A patent/EP3344274A4/en not_active Withdrawn
-
2018
- 2018-02-28 IL IL257801A patent/IL257801A/en unknown
- 2018-03-01 MX MX2022014310A patent/MX2022014310A/es unknown
- 2018-03-01 MX MX2023014409A patent/MX2023014409A/es unknown
- 2018-03-01 PH PH12018500448A patent/PH12018500448A1/en unknown
- 2018-03-28 CO CONC2018/0003465A patent/CO2018003465A2/es unknown
- 2018-10-29 US US16/173,667 patent/US10772854B2/en active Active
-
2020
- 2020-01-09 US US16/738,618 patent/US10744103B2/en active Active
- 2020-01-09 US US16/738,695 patent/US10799468B2/en active Active
- 2020-02-28 US US16/805,245 patent/US10905666B2/en active Active
- 2020-02-28 US US16/805,393 patent/US10912746B2/en active Active
- 2020-05-11 US US16/871,717 patent/US10849867B2/en active Active
- 2020-05-13 US US15/931,320 patent/US20200276140A1/en not_active Abandoned
-
2021
- 2021-02-01 US US17/163,996 patent/US11793777B2/en active Active
- 2021-02-08 US US17/169,980 patent/US20220000812A1/en not_active Abandoned
- 2021-03-09 JP JP2021036866A patent/JP7189983B2/ja active Active
- 2021-03-15 CL CL2021000622A patent/CL2021000622A1/es unknown
-
2023
- 2023-03-15 US US18/121,795 patent/US20240074995A1/en not_active Abandoned
- 2023-05-30 AU AU2023203354A patent/AU2023203354A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2018000069A1 (en) | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | |
| WO2017011820A3 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| EP4378536A3 (en) | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | |
| MX2018012249A (es) | Moduladores de nlpr3. | |
| WO2015077503A8 (en) | Autotaxin inhibitor compounds | |
| WO2015148863A3 (en) | Crispr/cas-related methods and compositions for treating sickle cell disease | |
| WO2015067715A3 (en) | Gip-glp-1 dual agonist compounds and methods | |
| MX2017007478A (es) | Compuestos inhibidores. | |
| WO2015006555A3 (en) | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use | |
| PH12015501697A1 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
| HK1206726A1 (en) | Imidazotriazinone compounds | |
| WO2014151456A3 (en) | Treatment of inflammatory diseases | |
| MX2022010638A (es) | Inhibidores de pde9 para el tratamiento de enfermedades perifericas. | |
| PH12017500114A1 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
| PH12020500204A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease | |
| MX363385B (es) | Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias. | |
| WO2012102560A3 (ko) | 신규한 4-ｏ-메틸호노키올 유도체 및 이를 유효성분으로 포함하는 염증질환 치료용 조성물 | |
| MX2016003725A (es) | Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau. | |
| WO2017009257A3 (en) | Pectin compositions for preventing and treating inflammatory diseases | |
| WO2015095789A3 (en) | Suppression of allergic lung inflammation and hyperreactivity | |
| CL2018000559A1 (es) | Métodos y composiciones para tratar condiciones asociadas con respuestas inflamatorias anormales | |
| WO2016144704A3 (en) | Heterocyclic autotaxin inhibitor compounds | |
| UA94737C2 (ru) | Соединения на основе имидазола, композиция, которая их содержит, и их применение | |
| PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
| IN2013MU03429A (https=) |